DRUG · Unmapped registry intervention
Human regular U-500 insulin (CSII)
Find medicine records ·
Find other trials using this name
Clinical trial
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
NCT02561078
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Human regular U-500 insulin (MDI)
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedAn Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Insulet Corporationcollaborator
Mapped research locations
Las VegasNevada, United States2San JuanPuerto Rico2ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1NashvilleTennessee, United States1PittsburghPennsylvania, United States1PortlandOregon, United States1JacksonvilleFlorida, United States1Oklahoma CityOklahoma, United States1AustinTexas, United States1OmahaNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02561078 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.